HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and a diagnostic service.
HIPRA has a international presence in more than 40 countries with its own subsidiaries, 3 R&D centres and production plants located in Europe (Spain) and America (Brazil).
In addition, its international distribution network maintains open distribution channels with more than 100 countries, covering all 5 continents.
Since 2020, the company has been developing a vaccine against COVID-19.
History
The beginnings date back to 1971 when a group of young entrepreneurs acquired a small laboratory in Madrid founded in 1954, called HIPRA (by the surnames of its former creators: Hidalgo and Prada), and moved to Amer (Girona).
During 1991, with a workforce of 100 people and a turnover of 10 million euros, was a crucial year in HIPRA's history. A new management team redefines the company's expansion policy.
As of 2000, the company began the internationalization of HIPRA with the implementation of its own subsidiaries around the world. Currently HIPRA has commercial subsidiaries in 40 countries, 3 research centers and 6 production plants located in Europe and America. Its distribution network covers the 5 continents.
In 2009 the positioning was refined to focus on prevention, with different and products and, therefore, it stopped investing in pharmacological products.
In 2020, and in a context of the Covid-19 pandemic, a new challenge was faced using its experience in vaccines, the development of the vaccine against this new virus based on recombinant protein.
In 2021 the new Human Health division was created to develop new products. The same year GoodGut was acquired, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases.
Animal health
HIPRA has developed more than 100 vaccines for different animal species, both production and companion animals, against a wide variety of biological targets. In addition to its Amer plant, the company has another plant in Brazil, in the Porto Alegre conurbation. It also has a university research centre in the United States.
HIPRA's animal health products include vaccines, vaccination devices, integrated traceability services and diagnostic kits.